Exam II Flashcards
proteins purpose
- bind to other molecules to mediate critical biological processes
- catalyze chemical reactions
- control signaling pathways
- structural proteins maintain cellular architecture and function
4 levels of protein structure
Primary: amino acid sequence; nothing to do with structure
Secondary: local structures folding (helices/sheets); hydrogen bonding
Tertiary: local conformations fold into 3D structure of a protein
Quaternary: multiple chains of proteins that associate into multi-protein complexes
primary
Defined by amino acids sequences
Proteins are polymers of 20 amino acids
Common backbone, variable side chains
Side chains determine differences between identities/charges
Folding allows charges to interact
protein stabilization/folding
Specific interactions stabilize protein shapes/determine how they fold
Covalent/Disulfide bonds, Salt bridge, Hydrogen bond, Long-range electrostatic interaction, VDW interactions
hydrophobic: protein core
other interactions: allow side chains to interact/fold
secondary
Regularly repeating backbone conformations, held in place by hydrogen bonds
Backbones of AA interact with one another through H-bonds
AAs that interact in the local structures can be far apart in sequence, but close together in structure
BETA SHEETS
ALPHA HELICES
SURFACE LOOPS
beta sheets
Provide stability through H-bonding
Strands run parallel or antiparallel to each other with H bonding between backbone groups
Alternates H-bonds between the backbone atoms (acceptors and donors)
Hydrogen-bonding amino acids are distant from each other in terms of sequence
Alpha Helices
Most common secondary structure in proteins
Hydrogen bonding between C=O/N-H groups that are four residues apart
H-bonding AAs are close together in terms of sequence
Can be amphipathic: having hydrophilic and hydrophobic sides
Helps proteins associate with membranes and stabilize structures
Surface Loops
Provide flexibility and binding specificity
Not structured; no regular backbone conformation
Good for binding site
Loops on surface (compared to AH/BS in backbone of protein) interact with small molecules
Tertiary
Structure arises from folded secondary elements
Pack secondary-structure elements together
Very complex, so many degrees of freedom (rotatable bonds), but typically folds into determined 3D conformation
oligomers
more than one polypeptide chain
Homo: 1 kind of sequence/chain
Hetero: different sequences/chains
Quaternary
Involves multiple chains (monomers assemble into larger protein oligomer)
dimer, trimer, tetramer…
monomers
individual oligomer chains
drug target
biological entity (proteins/nucleic acids) to which a drug/ligand can bind
Binding alters drug target activity
classified by interactions/role: protein, nucleic acid, lipid
pockets VS surfaces
Surfaces BAD; Pockets GOOD (well-defined pocket good for fitting small molecule)
Protein-protein interactions are much harder to inhibit than enzymes with small molecule substrates
Good Drug Target Qualities
- pocket vs surface
- essential to disease
- specific pocket
– common shaped pockets can cause excessive binding and many side effects
ligands
anything that binds to a protein/drug target → proteins, nucleic acids, small molecules
drugs / drug types
Substance that causes physiological change in the body (often a ligand)
Biologics: drugs from biology
(Antibodies, vaccines, gene therapies, stem-cell therapies)
Small-molecule drugs: synthesized molecules
Drug classifications
- Pharmacological effect
- Target system
- Site of action
- Structure/family of molecules
agonist VS antagonist
Agonist: binds and alters activity of receptor
Antagonist: binds, but doesnt not alter activity of receptor, but blocks (competitive) or dampens (allosteric) action of the agonist; reduces activity by preventing other binding
Effect: Agonists activate receptors, while antagonists block them.
Action: Agonists mimic natural substances, while antagonists oppose them.
Response: Agonists produce a response, while antagonists prevent a response.
metabolite analogs
Mimic natural molecules for therapeutic effects
- Starts with a bioactive molecule
- Modify to it still binds to a target, BUT doesnt have the same biological effect
Disadvantage: binding promiscuity (ex/ ATP analog will bind to many pockets)
high throughput screening (HTS)
Tests thousands of compounds for activity
targets cells, tissues, and proteins
Uses robotics, data processing, and control software, liquid handling devices, and sensitive detectors
Allows screening in 384, 1536, or 3456 well formats
UltaHTS (uHTS) enables testing of 100,000+ compounds per day!
2 types of HTS
- phenotypic screening
- receptor-centric screens
Phenotypic screens
Testings 100,000s of compounds for effects on cells/tissues
Very expensive
UNKNOWN DRUG TARGET
Can see how effects the whole cell overall
Phenotypic screening does not reveal:
- Why a compound is active
- If a compound is specific for a given target
receptor-centric screening
Testing 100,000s of compounds for effects on specific proteins
Often miniaturized enzymatic assays
Virtual screening…doing this in silico
KNOWN TARGET CELL